Bennett Smith explores why biopharma startups may find more success by starting small, focusing on targeted wins, and building sustainable growth instead of chasing massive markets.
Congress finally reauthorized the Rare Pediatric Disease Priority Review Voucher program, after it expired in 2024. That matters a lot to patients and drug developers, writes George Magrath, M.D.
In the AI era, thriving life sciences organizations will differentiate themselves based on their ability to combine AI's power with distinctly human capabilities, writes Christine Ann Miller.
